Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

(MedPage Today) -- Second-line treatment with an investigational anti-CTLA-4 immunotherapy improved survival in squamous non-small cell lung cancer (NSCLC) compared with chemotherapy, according to results of the phase III PRESERVE-003 trial. Among...